We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Bioavailability Study of Metronidazole Capsules Under Fed Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01380522
Recruitment Status : Completed
First Posted : June 27, 2011
Last Update Posted : June 27, 2011
Algorithme Pharma Inc
Information provided by:
Par Pharmaceutical, Inc.

Brief Summary:
The purpose of this study is to compare the single-dose Bioavailability of Kali and G.D. Searle, Inc.

Condition or disease Intervention/treatment Phase
To Determine the Bioequivalence Study Under Fed Drug: Metronidazole Drug: Flagyl Phase 1

Detailed Description:
To compare the relative Bioavailability of Metronidazole 375 mg Capsules with that of Flagyl 375 mg Capsules in healthy, adult subjects under fed conditions

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: To Compare the Relative Bioavailability of 375 mg Metronidazole Capsules (Kali) With That of Flagyl 375 mg Capsules/( G.D. Searle, Inc) Under Fed Conditions
Study Start Date : August 2002
Actual Primary Completion Date : September 2002
Actual Study Completion Date : September 2002

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malnutrition

Arm Intervention/treatment
Experimental: A
Subjects received kali product under fed conditions
Drug: Metronidazole
Capsules, single-dose, fed
Other Name: Flagyl

Active Comparator: B
Subjects received Searle product under fed conditions
Drug: Flagyl
Capsules, single-dose, fed
Other Name: Metronidazole Capsules

Primary Outcome Measures :
  1. Bioequivalence
    To conclude bioequivalence the exponential of the difference between the test and reference product for Cmax, AUCt and AUC∞ should be between 80 and 125%.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects meeting all the following criteria may be included in the study
  • Availability of subjects for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form duly signed by the subject.
  • Males or females aged from 18 to 50 years with a body mass index (BMI) within 19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report.
  • Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance and must be recorded as such in the Case Report Forms (CRF) (laboratory tests are presented in section 7.1.3)
  • Healthy according to the laboratory results and physical examination
  • Subjects should be non-or ex-smokers

Exclusion Criteria:

  • Significant history of hypersensitivity to metronidazole or any related products as well as sever hypersensitivity reactions (like angioedema) to any drugs.
  • Presence or history of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
  • Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease.
  • Females who are pregnant, lactating or are likely to become pregnant during the study periods.
  • Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the study.
  • Positive pregnancy test before or during the study.
  • Presence or history of significant thyroid dysfunction (hypo or hyperthyroidism).
  • Presence or history of significant hypoadrenalism.
  • Presence or history of significant blood disorders (thrombocytopenia, hemophilia, bleeding, etc.).
  • Presence or history of significant neurological disorders.
  • Maintenance therapy with any drug, or significant history of drug dependency, alcohol abuse (>3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious psychological disease.
  • Any clinically significant illness in the previous 28 days before day 1 of this study.
  • Use of enzyme-modifying drugs in the previous 28 days before day 1 of this study (all barbiturates, corticosteroids, phenylhydantoins, etc.).
  • Participation in another clinical trial in the previous 28 days before day 1 of this study.
  • Donation of 500mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 5 days before day 1 of this study.
  • Positive urine screening of drugs of abuse (drug names are presented in section 7.1.4.).
  • Positive results to HIV, HBsAg or anti-HCV tests.
  • History of fainting upon blood sampling.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01380522

Layout table for location information
Canada, Quebec
Algorithme Pharma Inc
Montreal, Quebec, Canada, H4N 2Y8
Sponsors and Collaborators
Par Pharmaceutical, Inc.
Algorithme Pharma Inc
Layout table for investigator information
Principal Investigator: Christian Aumais, M.D Algorithme Pharma Inc
Layout table for additonal information
Responsible Party: Dr. Alfred Elvin/ Director Biopharmaceutics, Par Pharmaceutical, Inc.
ClinicalTrials.gov Identifier: NCT01380522    
Other Study ID Numbers: MTL-P2-156
First Posted: June 27, 2011    Key Record Dates
Last Update Posted: June 27, 2011
Last Verified: June 2011
Keywords provided by Par Pharmaceutical, Inc.:
Bioequivalence, single-dose, fed
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrition Disorders
Anti-Infective Agents
Anti-Bacterial Agents
Antiprotozoal Agents
Antiparasitic Agents